Skip to main content
Clinical Trials/NCT03586492
NCT03586492
Completed
Not Applicable

SPECT Myocardial Perfusion Reserve Using a Cadmium Zinc Telluride (CZT) Camera in Cardiovascular Risk Stratification and Ischemia

Centre Hospitalier Régional d'Orléans2 sites in 1 country137 target enrollmentNovember 5, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ischemia, Myocardial
Sponsor
Centre Hospitalier Régional d'Orléans
Enrollment
137
Locations
2
Primary Endpoint
Regional and global CFR
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

CFR has been studied for few years using 82 Rubidium PET (positron emission tomography) /CT. CFR has shown to be correlated with cardiovascular events occurring in the 10 following years. CFR also helps to identify multivessel coronary disease. Few studies have shown the possibility to calculate CFR during myocardial perfusion SPECT on new ultrafast CZT cameras.

Detailed Description

Evaluate the contribution of CZT SPECT CFR in cardiovascular risk stratification: correlation with clinical scores, with calcium score, and when pathological with coronarography findings especially fractional flow reserve (FFR).

Registry
clinicaltrials.gov
Start Date
November 5, 2018
End Date
November 5, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients referred for myocardial ischemia screening

Exclusion Criteria

  • Patient already suffering from coronary disease with angioplasty, bypass surgery or myocardial infarction.
  • Contraindications related to the stress test:
  • Acute Coronary Syndrome \<5 days Unstable angina Stenosis of left main artery untreated Uncontrolled severe rhythm disorders Uncontrolled heart failure
  • Contraindications to dipyridamole and regadenoson:
  • Hypotension (systolic \<90mmHg) Severe pulmonary arterial hypertension Bradycardia \<40 beats / minute Sinusal Dysfunction and 2nd or 3rd degree Atrioventricular block Decompensated Heart Failure with Ejection Fraction \<25% Stenosis of supra-aortic trunks unilateral\> 70% or bilateral\> 50% Dipyridamole and regadenoson allergy
  • Patients with pacemaker, or who have had valvular surgery,
  • Well-known dilated cardiopathy
  • Pregnant or breastfeeding women,
  • Minor people
  • Persons under guardianship or under guardianship

Outcomes

Primary Outcomes

Regional and global CFR

Time Frame: Day 0

Regional and global CFR calculated from CZT SPECT myocardial perfusion: correlation with clinical score and calcium score

Secondary Outcomes

  • FFR Regional CFR after one year of medical treatment(Up to one year)

Study Sites (2)

Loading locations...

Similar Trials